Lv4
405 积分 2020-08-03 加入
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer
2天前
已完结
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
8天前
已完结
Treating EGFR-mutant nonsmall cell lung cancer is no longer a one-size-fits-all approach
10天前
已完结
Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study
11天前
已关闭
Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography–tandem mass spectrometry
12天前
已完结
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
13天前
已完结
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
13天前
已完结
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
13天前
已完结
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives
13天前
已完结
Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations
13天前
已完结
皖公网安备34019202002308
